Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
06/02/2000 | CA2351354A1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
06/02/2000 | CA2351311A1 Uses for eph receptor antagonists and agonists to treat vascular disorders |
06/02/2000 | CA2350405A1 Method of using pon-1 to decrease atheroma formation |
06/02/2000 | CA2350395A1 Nucleotide and protein sequences of nogo genes and methods based thereon |
06/02/2000 | CA2349555A1 Composition and use of rar antagonists for promoting chondrogenesis |
06/02/2000 | CA2349290A1 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof |
05/31/2000 | EP1004674A1 Human adamts-1 protein, gene coding for the same, pharmaceutical composition, and method for immunologically assaying human adamts-1 protein |
05/31/2000 | EP1004670A2 Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents |
05/31/2000 | EP1004669A1 Novel differentiation inhibitor |
05/31/2000 | EP1004666A1 Protein having pdz domain sequence |
05/31/2000 | EP1004664A1 Compositions and methods using lactadherin or variants thereof |
05/31/2000 | EP1004595A2 Lytic and proliferative peptides and their use as pharmaceutic and phytopharmaceutic agents |
05/31/2000 | EP1004319A1 Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors |
05/31/2000 | EP1004315A1 Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient |
05/31/2000 | EP1004313A1 Cachexia remedy |
05/31/2000 | EP1004312A1 Method for treating multiple sclerosis |
05/31/2000 | EP1004302A2 Immunomodulator |
05/31/2000 | EP1003898A1 Integrin-targeting vectors having transfection activity |
05/31/2000 | EP1003897A1 Complexes for transporting nucleic acid into eukaryotic higher-cells |
05/31/2000 | EP1003894A2 Lentiviral vectors |
05/31/2000 | EP1003880A2 Human ubiquitin carrier protein e2-like protein and cyclin b-like protein |
05/31/2000 | EP1003870A1 A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same |
05/31/2000 | EP1003866A1 Method for identifying and locating expressed epil peptides, coded by the insl4 gene and their uses |
05/31/2000 | EP1003862A1 Human longevity-assurance protein homologs |
05/31/2000 | EP1003861A2 Mammalian cell membrane proteins; related reagents |
05/31/2000 | EP1003859A1 Use of transcription factor brn-3a |
05/31/2000 | EP1003858A1 New human growth regulator protein |
05/31/2000 | EP1003857A2 Secreted proteins and polynucleotides encoding them |
05/31/2000 | EP1003856A1 Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
05/31/2000 | EP1003855A2 Secreted proteins and polynucleotides encoding them |
05/31/2000 | EP1003854A1 Antimicrobial peptides derived from ubiquicidine |
05/31/2000 | EP1003851A2 Syncytial respiratory virus epitopes and antibodies comprising them, useful in diagnosis and therapy |
05/31/2000 | EP1003850A1 Inhibitors of dna immunostimulatory sequence activity |
05/31/2000 | EP1003842A1 Catalytic monoclonal antibodies for the in vivo transformation of corticosteroid prodrugs |
05/31/2000 | EP1003787A2 Agent for the treatment and/or prophylaxis of microcirculation disorders |
05/31/2000 | EP1003786A1 Peptide with radio protective effect |
05/31/2000 | EP1003784A1 Novel peptides and polypeptides useful for regenerating the nervous system |
05/31/2000 | EP1003783A2 Lipoprotein-regulating medicaments |
05/31/2000 | EP1003782A1 Ligand for herpes simplex virus entry mediator and methods of use |
05/31/2000 | EP1003781A1 Interleukin-18 binding proteins, their preparation and use |
05/31/2000 | EP1003780A1 Human f11 antigen: a cell surface receptor involved in platelet aggregation |
05/31/2000 | EP1003777A1 PGC-1, A NOVEL BROWN FAT PPAR$g(g) COACTIVATOR |
05/31/2000 | EP1003776A1 Gene and amino acid sequences for novel transcription factor |
05/31/2000 | EP1003775A2 Hepatitis c inhibitor peptides |
05/31/2000 | EP1003774A1 GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6 |
05/31/2000 | EP1003772A1 Chemical modification of proteins to improve biocompatibility and bioactivity |
05/31/2000 | EP1003771A1 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances |
05/31/2000 | EP1003770A1 Secreted proteins and polynucleotides encoding them |
05/31/2000 | EP1003768A1 Secreted proteins and polynucleotides encoding them |
05/31/2000 | EP1003767A1 Human tumor necrosis factor receptor tr10 |
05/31/2000 | EP1003763A1 83 human secreted proteins |
05/31/2000 | EP1003577A1 Blood product delivery system |
05/31/2000 | EP1003552A1 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION |
05/31/2000 | EP1003550A1 Receptor specific transepithelial transport of therapeutics |
05/31/2000 | EP1003548A1 A method of inducing a ctl response |
05/31/2000 | EP1003547A1 Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis |
05/31/2000 | EP1003546A1 Methods for treatment of patients afflicted wih multiple sclerosis using consensus interferon |
05/31/2000 | EP1003545A1 Heparin-binding growth factor (hbgf) polypeptides |
05/31/2000 | EP1003544A1 C1q AND COLLECTIN RECEPTOR |
05/31/2000 | EP1003543A1 Apoptosis-inducing gelsolin sequences |
05/31/2000 | EP1003542A1 Use of substances having oxytocin activity for preparation of medicaments for wound healing |
05/31/2000 | EP1003541A1 Inhibitors of hiv reverse transcriptase |
05/31/2000 | EP1003540A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
05/31/2000 | EP1003539A1 FLUORESCENT AMYLOID A$g(b) PEPTIDES AND USES THEREOF |
05/31/2000 | EP1003533A1 Use of herpes vectors for tumor therapy |
05/31/2000 | EP1003532A1 Absorption of minerals by intestinal cells |
05/31/2000 | EP1003530A1 Eye treatments using synthetic thyroid hormone compositions |
05/31/2000 | EP1003526A1 Covalently linked n,o-carboxymethylchitosan and uses thereof |
05/31/2000 | EP1003500A1 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
05/31/2000 | EP1003483A1 Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
05/31/2000 | EP1003481A1 Fibrinogen-coated microspheres |
05/31/2000 | EP1003480A1 Conjugated peptide nucleic acids having enhanced cellular uptake |
05/31/2000 | EP1003478A1 Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols |
05/31/2000 | EP1003379A1 Novel phytase |
05/31/2000 | EP1003370A1 Method of enhancing magnesium absorption and prevention of atherosclerosis |
05/31/2000 | EP1003365A1 Atrial natriuretic factor mutants and ischemic stroke |
05/31/2000 | EP0944650B1 Antithrombotic peptides derived from fibronectin type ii repeats |
05/31/2000 | EP0939651B1 Materials and methods relating to the diagnosis and treatment of pre-eclampsia |
05/31/2000 | EP0828854B1 Analytical and therapeutic agents |
05/31/2000 | EP0818462A4 Peptide and a method of obtaining it |
05/31/2000 | EP0747033B1 Transfusion liquid-containing holder and prepared transfusion liquid |
05/31/2000 | EP0746337B1 Verotoxin pharmaceutical compositions and medical treatments thereof |
05/31/2000 | EP0728207B1 Telomerase activity assays |
05/31/2000 | EP0635016B1 Benzodiazepine derivatives and protein and polypeptide conjugates thereof |
05/31/2000 | EP0631619B1 Reconstituted cartilage tissue |
05/31/2000 | EP0584082B1 Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
05/31/2000 | EP0464022B1 Insulinotropic hormone |
05/31/2000 | DE19854749A1 Verwendung von Kapseln, die eine oder mehrere antigene Substanzen enthalten, zur Prävention und/oder Behandlung von Autoimmunerkrankungen The use of capsules which contain one or more antigenic substances, for the prevention and / or treatment of autoimmune diseases |
05/31/2000 | CN1255164A Modified antisense nucleotides complementary to section of human Ha-Ras gene |
05/31/2000 | CN1255163A Compounds |
05/31/2000 | CN1255162A Protease inhibitors |
05/31/2000 | CN1255143A Novel strain of bacillus for controlling plant diseases and corn rootworm |
05/31/2000 | CN1255066A Plant extracts for the treatment of increase bone resorption |
05/31/2000 | CN1255063A Photosensitizer conjugates for pathogen targeting |
05/31/2000 | CN1255044A Orally active fraction of momordica charactia, active peptides thereof, and their use in the treatment of diabetes |
05/31/2000 | CN1254729A Biologic medical equipment with antimicrobe coating |
05/31/2000 | CN1254558A S-(3-hydroxypropyl)-L-cysteine composition as oral medicine |
05/30/2000 | US6069242 Mixture of pharmaceutically acceptable carrier and antisense nucleic acid; for diagnosis, imaging, anticarcinogenic agents, antitumor agents |
05/30/2000 | US6069239 Expression system present in compatible host cell which produces a ligand regulated transcription factor; antiinflammatory/antiarthritic/antidiabetic agents; treatment of autoimmune diseases; diagnosis of related diseases |
05/30/2000 | US6069236 Desalting, chromatography on anion exchange gel, viral deactivation using solvent-detergent treatment, chromatography on cation exchange gel, recovering; does not cause aggregate-induced complement activation |